Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac potassium + lidocaine is a combination medication that pairs two active ingredients with complementary mechanisms of action for pain relief. Diclofenac potassium is a non-steroidal anti-inflammatory drug (NSAID) that works by blocking cyclooxygenase enzymes (COX-1 and COX-2), which reduces the production of prostaglandins responsible for pain and inflammation[4]. Lidocaine is a local anesthetic that numbs nerves by blocking sodium-potassium channels, making them less sensitive to pain signals[3][4]. This combination is used for various pain conditions, including arthritis pain, musculoskeletal pain, and procedural pain. Clinical studies have shown that the combination slightly reduces pain scores during procedures like intrauterine device (IUD) insertion, though the reduction may not always reach clinical significance[1]. The topical formulation allows for local pain relief while potentially reducing systemic side effects compared to oral administration of NSAIDs[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac potassium + lidocaine.